[Castleman disease]

Véronique Meignin; Julien Calvani; Eric Oksenhendler

doi:10.1016/j.annpat.2022.07.013

[Castleman disease]

Ann Pathol. 2023 Jan;43(1):13-24. doi: 10.1016/j.annpat.2022.07.013. Epub 2022 Sep 30.

[Article in French]

Authors

Véronique Meignin¹, Julien Calvani², Eric Oksenhendler³

Affiliations

¹ Service de pathologie, Hôpital Saint Louis, Université de Paris, Paris, France. Electronic address: veronique.meignin@aphp.fr.
² Service de pathologie, Hôpital Saint Louis, Université de Paris, Paris, France.
³ Département d'immunologie Clinique, Hôpital Saint-Louis, Université de Paris, Paris, France.

PMID: 36192235
DOI: 10.1016/j.annpat.2022.07.013

Abstract

The term "Castleman disease" covers a variety of entities that have very different clinical, biological, pathological and physiopathological features. In this issue, we review the characteristics of the unicentric Castleman disease, of the HHV8 associated multicentric Castleman disease and the idiopathic multicentric Castleman disease associated or not with TAFRO syndrome ("thrombocytopenia, anasarca, fever, reticulin myelofibrosis and/or renal insufficiency, organomegaly"). We detail the differential diagnostics of these entities.

Keywords: Castleman disease; HHV8; Maladie de Castleman; Multicentric; Multicentrique; Uncentric; Unicentrique.

Publication types

Review
English Abstract

MeSH terms

Castleman Disease* / diagnosis
Castleman Disease* / pathology
Edema / pathology
Humans
Renal Insufficiency*
Thrombocytopenia* / complications
Thrombocytopenia* / pathology

Supplementary concepts

Multi-centric Castleman's Disease